Moderna
MRNA
#1830
Rank
A$16.29 B
Marketcap
A$41.70
Share price
8.67%
Change (1 day)
-37.36%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Moderna (MRNA) - Total debt

Total debt on the balance sheet as of September 2025 : A$1.10 Billion

According to Moderna 's latest financial reports the company's total debt is A$1.10 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Moderna - Total debt on balance sheet (from 2017 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$1.20 B-34.17%
2023-12-31A$1.82 B3.46%
2022-12-31A$1.76 B39.57%
2021-12-31A$1.26 B309.93%
2020-12-31A$0.30 B63.03%
2019-12-31A$0.18 B297.69%
2018-12-31A$47.53 M136.58%
2017-12-31A$20.09 M15.87%
2016-12-31A$17.34 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Regulus Therapeutics
RGLS
A$2.1 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
A$62.28 B 5,536.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A$27.96 M-97.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
A$1.96 B 78.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$48.20 B 4,262.67%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Arrowhead Pharmaceuticals
ARWR
A$0.53 B-51.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
A$68.94 B 6,139.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA